glp-1 for perimenopause weight gain Agonists in Perimenopause: Unique Risks and Potential Opportunities Weight Gain During Menopause: Solutions

[DOI] [PubMed] [Google Scholar] 63

Reduces appetite and increases feelings of fullness (satiety), leading to reduced caloric intake

Candidate patient groups for such dual-treatment approaches may include IBD patients with elevated BMI, those at increased risk of metabolic complications, patients receiving therapies associated with heightened cardiovascular risk, and overweight individuals with IBD who are candidates for surgical intervention

Dopamine, which acts as a neurotransmitter, is known to play a key role in movement control

In particular, tell your provider if you have a past history of: Type 1 or type 2 diabetes Thyroid cancer Gastrointestinal disease Pancreatitis Kidney disease Diabetic retinopathy Depression Suicidal thoughts or behavior Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding

In preclinical models, direct activation of GLP-1Rs in the NTS reduces food and drug intake, whereas knockdown of GLP-1R in this region reverses these effects [20,35]